Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.50

+4.7%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$161.19M
EPS-1.6700
P/E Ratio-4.49
Earnings Date08/13/2026

uncy

Stock Based Compensation

Last Annual Value

2.64M

3-Year CAGR

36%

5-Year CAGR

63%

10-Year CAGR

%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Stock Based Compensation

UNCY · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.64M
14.3%22.3%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
8.31M
-16.2%-1.3%15.9%
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
8.19M
N/A31.4%24.1%
28.74M
19.1%8.1%9.0%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
1.54M
27.6%11.4%69.7%
IMA logo
ImageneBio Inc
NASDAQ:IMA
15.39M
N/A24.3%N/A
7.00M
0.3%5.1%N/A
5.92M
-21.8%N/AN/A
445.00K
-38.8%-30.5%N/A
14.72M
8.2%96.9%N/A
9.52M
-12.3%N/AN/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.5, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.5